Position in CDXS
as of Mar 31, 2026
· filed May 21, 2026
Position Value
$13,020
New position
Shares Held
7,988
first reported quarter
Ownership
0.009%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Essential Partners LLC holds $6,266,864 across 181 Biotechnology names. CDXS ranks #41 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
28,674 | $2,698,796 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
735 | $567,890 | |
| 3 | EXEL |
Exelixis, Inc.
|
12,527 | $537,283 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
8,777 | $495,812 | |
| 5 | GLUE |
Monte Rosa Therapeutics, Inc.
|
13,028 | $214,310 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
2,369 | $161,399 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
5,784 | $125,859 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
9,675 | $91,138 |
All Filings in CDXS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13,020 | 7,988 | Shares | Sole | 2026-05-21 | |
| No filing history on record for this holder in this stock. | ||||||